Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» CLL
CLL
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Flag link:
Secura Bio to keep offering blood cancer drug despite negative ODAC vote, OS questions
Secura Bio to keep offering blood cancer drug despite negative ODAC vote, OS questions
Endpoints
Secura Bio
Copiktra
CLL
small lymphocytic lymphoma
FDA
Flag link:
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
Flag link:
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
BeiGene
Brukinsa
CLL
FDA
Imbruvica
Flag link:
TG slips out a nasty surprise for investors
TG slips out a nasty surprise for investors
EP Vantage
TG Therapeutics
FDA
CLL
clinical hold
Flag link:
Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells
Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells
Fierce Biotech
Novarts
CAR-T
CLL
Kymriah
Flag link:
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
Fierce Pharma
BeiGene
Brukinsa
CLL
small lymphocytic lymphoma
clinical trials
Flag link:
In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
Endpoints
AstraZeneca
JNJ
AbbVie
clinical trials
CLL
Gazyva
Imbruvica
Venclexta
Flag link:
AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO
AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO
BioSpace
AstraZeneca
ASCO 2021
breast cancer
CLL
Lynparza
Calquence
Flag link:
TG Therapeutics completes FDA filing for Roche challenger in CLL
TG Therapeutics completes FDA filing for Roche challenger in CLL
Pharmaforum
TG Therapeutics
FDA
antibodies
CLL
ublituximab-umbralisib
Flag link:
AZ says Calquence is a safer drug than Imbruvica
AZ says Calquence is a safer drug than Imbruvica
Pharmaforum
AstraZeneca
Calquence
Imbruvica
JNJ
AbbVie
CLL
Flag link:
TG Therapeutics set for upsized IPO to develop cancer combination drug
TG Therapeutics set for upsized IPO to develop cancer combination drug
Pharmaforum
TG Therapeutics
ASH2020
IPOs
CLL
Flag link:
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Flag link:
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
rituximab
CLL
Flag link:
AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise
AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise
Endpoints
AbbVie
JNJ
Imbruvica
FDA
CLL
SLL
Flag link:
Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Pharmaceutical Business Review
Janssen
JNJ
EMA
Imbruvica
CLL
Flag link:
Leukemia rivals try to stay ahead as Merck, Lilly chase
Leukemia rivals try to stay ahead as Merck, Lilly chase
Biopharma Dive
Merck
Eli Lilly
AbbVie
JNJ
Imbruvica
ARQ 531
LOXO-305
CLL
ASH2019
Flag link:
ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data
ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data
Fierce Biotech
Eli Lilly
Loxo Oncology
ASH2019
CLL
Flag link:
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
Pharmaforum
AstraZeneca
cancer
Calquence
ASH2019
Imbruvica
JNJ
AbbVie
CLL
Flag link:
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
Fierce Pharma
AbbVie
Roche
CLL
ASH2019
Venclexta
Flag link:
Pages
1
2
3
4
next ›
last »